Belgian Electrical Stock News

Retail Estates (ENXTBR:RET) has reported FY 2026 first half revenue of €71.3 million and basic EPS of €3.17, setting the tone for a year in which trailing twelve month revenue sits at €143.1 million and EPS of €7.57. Over recent periods, the company has seen revenue move from €69.9 million in H1 FY 2025 to €70.6 million in H2 FY 2025 and then to €71.3 million in H1 FY 2026, while EPS has shifted from €2.88 to €4.41 and now €3.17, rounding out a trailing net income of €123.0 million. With an...

Readers hoping to buy Texaf S.A. ( EBR:TEXF ) for its dividend will need to make their move shortly, as the stock is...

EVS Broadcast Equipment SA ( EBR:EVS ) stock is about to trade ex-dividend in 3 days. The ex-dividend date is commonly...

In the first quarter of 2026, Syensqo reported sales of €1,461 million, with net income improving to €62 million from a small loss a year earlier, and basic earnings per share rising to €0.60. Ahead of these results, the company launched a review of its Performance & Care segment to sharpen its focus on specialty materials and advanced technologies across sectors such as aerospace, electronics, healthcare, energy, and advanced mobility. We’ll now consider how the Performance & Care segment...

Sofina Société Anonyme (ENXTBR:SOF) has announced an annual dividend of €2.5620 per share, with the ex dividend date on 27 May 2026, the record date on 28 May and payment on 29 May. See our latest analysis for Sofina Société Anonyme. The dividend announcement comes as Sofina Société Anonyme’s share price, currently at €222.4, has risen 1.92% over the last day and 4.81% over the last week, while its 1-year total shareholder return is down 12.53% but up 16.68% over three years. This indicates...

DEME Group NV ( EBR:DEME ) stock is about to trade ex-dividend in four days. The ex-dividend date generally occurs two...

KBC Group (ENXTBR:KBC) is back in focus after first quarter 2026 results and a higher full year 2025 dividend were released, with upcoming fixed income calls providing another touchpoint for investors. See our latest analysis for KBC Group. Despite a 1 day share price return of 1.38% taking KBC Group to €110.35, the 30 day share price return is down 6.88%. The 1 year total shareholder return of 25.50% and 3 year total shareholder return of about 2x suggest momentum has been stronger over...

Jensen-Group NV ( EBR:JEN ) stock is about to trade ex-dividend in 4 days. Typically, the ex-dividend date is two...

Cmb.Tech NV ( EBR:CMBT ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...

Aedifica/SA (ENXTBR:AED) has opened Q1 2026 reporting season with revenue of €89.8 million for Q4 2025 and basic EPS of €1.06, supported by trailing twelve month revenue of €368.9 million and EPS of €5.14. Over recent quarters the company has seen revenue move from €87.4 million in Q4 2024 to €95.4 million in Q1 2025, before landing at €89.8 million in Q4 2025. Quarterly EPS ranged from €0.71 to €1.70 over the same stretch. For investors, the key question now is how these headline figures,...

Retail Estates (ENXTBR:RET) drew investor attention after the stock moved higher on strong trading volumes, supported by a 7.4% dividend yield, a 0.84x P/B ratio and a 31.3% rise in free cash flow. See our latest analysis for Retail Estates. The recent share price move comes on top of a 9.1% year to date share price return and a 13.7% total shareholder return over the past year. This suggests that momentum has been gradually building rather than fading. If this kind of income focused story...

In early May 2026, argenx SE received U.S. FDA approval to expand the VYVGART and VYVGART Hytrulo labels to treat all serotypes of adult generalized myasthenia gravis, supported by Phase 3 ADAPT SERON data showing rapid, clinically meaningful MG-ADL improvements and a safety profile consistent with prior use in anti-AChR-Ab positive patients. This expansion brings previously under-served groups, including anti-MuSK-Ab positive, anti-LRP4-Ab positive and triple seronegative patients, into...

Why UCB’s Korean access push matters for ENXTBR:UCB shareholders UCB (ENXTBR:UCB) is in focus after its Korean unit highlighted a renewed push on patient access, following recent reimbursement wins for Bimzelx and Fintepla and preparation for Rystiggo and Zilbrysq. See our latest analysis for UCB. The Korean access push lands at a time when UCB’s share price has eased, with a 30 day share price return down 11% and a 90 day share price return down 17.7%, yet its 1 year total shareholder return...

As European markets navigate the complexities of geopolitical tensions and inflationary pressures, the STOXX Europe 600 Index recently experienced a slight decline, reflecting broader market sentiment. Despite these challenges, small-cap stocks in Europe continue to present intriguing opportunities for investors seeking growth potential amidst robust earnings reports. In today's dynamic environment, identifying promising small-cap stocks involves looking for companies with strong...

Cmb.Tech (ENXTBR:CMBT) opened 2026 with a busy quarter, reporting Q1 revenue of US$807.3 million and basic EPS of US$1.27, while trailing twelve month revenue sat at US$2.2 billion with EPS of US$1.92. This gives investors a fresh read on both quarterly momentum and the rolling earnings base behind the current €14.58 share price. Over recent periods the company has seen revenue move from US$235.0 million in Q1 2025 and US$226.0 million in Q4 2024 to US$807.3 million in Q1 2026, with basic EPS...

Fagron (ENXTBR:FAGR) has just wrapped up its Annual and Extraordinary General Meeting, confirming new board appointments and approving a €0.40 gross dividend per share, with the ex-dividend date set for 18 May 2026. See our latest analysis for Fagron. Fagron’s recent AGM decisions and director confirmations come after a period where the stock has gained 11.72% year to date on a share price basis, and delivered a 44.36% total shareholder return over three years, suggesting momentum has been...

Ascencio (ENXTBR:ASCE) has reported its H1 2026 results with the trailing twelve months showing total revenue of €62.3 million and net income of €36.5 million, setting a clear baseline for how the business is currently performing. Over recent periods the company has seen revenue move from €28.4 million in H2 2024 to €34.2 million in H1 2025 and €28.2 million in H2 2025, while basic EPS shifted from €3.00 to €2.83 and then €2.57, which gives you a straightforward view of how the top line and...

Wondering if Umicore at €23.80 still offers value after a strong run, or if the easy gains are already behind it? This article focuses on what the current price might imply rather than trying to guess the next move. The stock has returned 6.0% over the past week, 31.7% over the past month, and 28.0% year to date, with a 172.8% return over the last year but declines of 10.1% over three years and 46.8% over five years. These mixed time frame returns are drawing attention back to the...

Proximus (ENXTBR:PROX) is back in focus after first quarter 2026 earnings showed lower sales and net income year over year, while its role in Ekinops’ new Network as a Service offer highlights its wholesale infrastructure. See our latest analysis for Proximus. The recent news around the earnings drop and the NaaS partnership appears to have landed in a mixed way with investors. The share price is at €6.69 after a 1-day share price return of 2.37% and a 90-day share price return that fell...

Investors may be asking whether NV Bekaert at €40.00 is offering good value right now, or if the recent run has already priced in the key positives. The stock is up 3.2% year to date and 20.6% over the past year. However, it has fallen 6.5% over the last week and 5.7% over the past month, which may reflect changing views on risk and return. Recent coverage has focused on NV Bekaert's share price performance over different time frames, giving investors more context on how the stock has...

Groupe Bruxelles Lambert (ENXTBR:GBLB) has released first quarter 2026 results, reporting sales of €1,631.5 million and net income of €64.6 million, giving investors fresh data on profitability trends. See our latest analysis for Groupe Bruxelles Lambert. The latest results come after a softer patch in the share price, with a 30 day share price return of down 5.46% and a 90 day share price return of down 6.98%. However, the 1 year total shareholder return of 12.57% and 3 year total...

argenx (ENXTBR:ARGX) is back in focus after the U.S. Food and Drug Administration approved a label expansion for VYVGART and VYVGART Hytrulo, covering all adult generalized myasthenia gravis serotypes. See our latest analysis for argenx. Despite the strong news flow around VYVGART and a recent earnings update, argenx’s share price return has been slightly weaker in the short term, with the stock down 3.43% over 30 days and 4.23% year to date. Longer term total shareholder returns of 36.73%...

Why Cmb.Tech is back on investors’ radar Cmb.Tech (ENXTBR:CMBT) has attracted fresh attention after its recent rebranding from Euronav NV and its shift toward low and zero carbon marine solutions, prompting investors to reassess the stock’s role in their portfolios. See our latest analysis for Cmb.Tech. Recent trading has been firmly positive, with the share price at €12.88 and a 30-day share price return of 14.39% adding to a 59.80% year-to-date share price return and a 55.35% 1-year total...

Umicore (ENXTBR:UMI) has caught investor attention after a sharp move recently, with the stock up around 33% over the past month and about 32% over the past 3 months. See our latest analysis for Umicore. Despite the latest share price of €24.08 pulling back with a 1-day share price return that declined 6.52%, momentum over the past month and year-to-date remains strong, while longer term total shareholder returns over three and five years have been weak. This mix of sharp recent gains and...